vs
COMMVAULT SYSTEMS INC（CVLT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
COMMVAULT SYSTEMS INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$311.7M vs $207.3M），COMMVAULT SYSTEMS INC净利率更高（4.7% vs -62.0%，领先66.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 13.3%），COMMVAULT SYSTEMS INC自由现金流更多（$131.8M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 17.8%）
Commvault Systems Inc.是美国上市的网络安全与数据保护软件企业，核心业务覆盖数据安全、云服务及基础设施管理领域，旗下方案广泛应用于各类企业的数据资产防护与IT架构运维场景，助力客户降低数据风险、提升云环境运营效率。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CVLT vs RARE — 直观对比
损益表 — Q4 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $311.7M | $207.3M |
| 净利润 | $14.6M | $-128.6M |
| 毛利率 | 81.4% | — |
| 营业利润率 | 5.3% | -54.7% |
| 净利率 | 4.7% | -62.0% |
| 营收同比 | 13.3% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.34 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $311.7M | — | ||
| Q4 25 | $313.8M | $207.3M | ||
| Q3 25 | $276.2M | $159.9M | ||
| Q2 25 | $282.0M | $166.5M | ||
| Q1 25 | $275.0M | $139.3M | ||
| Q4 24 | $262.6M | $164.6M | ||
| Q3 24 | $233.3M | $139.5M | ||
| Q2 24 | $224.7M | $147.0M |
| Q1 26 | $14.6M | — | ||
| Q4 25 | $17.8M | $-128.6M | ||
| Q3 25 | $14.7M | $-180.4M | ||
| Q2 25 | $23.5M | $-115.0M | ||
| Q1 25 | $31.0M | $-151.1M | ||
| Q4 24 | $11.0M | $-133.2M | ||
| Q3 24 | $15.6M | $-133.5M | ||
| Q2 24 | $18.5M | $-131.6M |
| Q1 26 | 81.4% | — | ||
| Q4 25 | 81.1% | — | ||
| Q3 25 | 80.1% | — | ||
| Q2 25 | 82.0% | — | ||
| Q1 25 | 82.6% | — | ||
| Q4 24 | 81.5% | — | ||
| Q3 24 | 81.6% | — | ||
| Q2 24 | 82.3% | — |
| Q1 26 | 5.3% | — | ||
| Q4 25 | 6.3% | -54.7% | ||
| Q3 25 | 4.5% | -106.9% | ||
| Q2 25 | 8.9% | -64.8% | ||
| Q1 25 | 9.7% | -102.6% | ||
| Q4 24 | 5.2% | -74.3% | ||
| Q3 24 | 6.4% | -94.6% | ||
| Q2 24 | 8.2% | -79.1% |
| Q1 26 | 4.7% | — | ||
| Q4 25 | 5.7% | -62.0% | ||
| Q3 25 | 5.3% | -112.8% | ||
| Q2 25 | 8.3% | -69.0% | ||
| Q1 25 | 11.3% | -108.5% | ||
| Q4 24 | 4.2% | -80.9% | ||
| Q3 24 | 6.7% | -95.7% | ||
| Q2 24 | 8.2% | -89.5% |
| Q1 26 | $0.34 | — | ||
| Q4 25 | $0.40 | $-1.28 | ||
| Q3 25 | $0.33 | $-1.81 | ||
| Q2 25 | $0.52 | $-1.17 | ||
| Q1 25 | $0.68 | $-1.57 | ||
| Q4 24 | $0.24 | $-1.34 | ||
| Q3 24 | $0.35 | $-1.40 | ||
| Q2 24 | $0.41 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $900.0M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.5M | $-80.0M |
| 总资产 | $1.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $900.0M | — | ||
| Q4 25 | $1.0B | $421.0M | ||
| Q3 25 | $1.1B | $202.5M | ||
| Q2 25 | $363.2M | $176.3M | ||
| Q1 25 | $302.1M | $127.1M | ||
| Q4 24 | $243.6M | $174.0M | ||
| Q3 24 | $303.1M | $150.6M | ||
| Q2 24 | $287.9M | $480.7M |
| Q1 26 | $7.5M | — | ||
| Q4 25 | $216.7M | $-80.0M | ||
| Q3 25 | $210.5M | $9.2M | ||
| Q2 25 | $364.7M | $151.3M | ||
| Q1 25 | $325.1M | $144.2M | ||
| Q4 24 | $287.8M | $255.0M | ||
| Q3 24 | $277.8M | $346.8M | ||
| Q2 24 | $281.8M | $432.4M |
| Q1 26 | $1.9B | — | ||
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.9B | $1.2B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.0B | $1.5B | ||
| Q3 24 | $958.5M | $1.5B | ||
| Q2 24 | $934.9M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $132.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $131.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | 42.3% | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 9.02× | — |
| 过去12个月自由现金流最近4个季度 | $237.2M | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | $132.2M | — | ||
| Q4 25 | $4.0M | $-99.8M | ||
| Q3 25 | $76.8M | $-91.4M | ||
| Q2 25 | $31.7M | $-108.3M | ||
| Q1 25 | $77.0M | $-166.5M | ||
| Q4 24 | $30.1M | $-79.3M | ||
| Q3 24 | $55.6M | $-67.0M | ||
| Q2 24 | $44.7M | $-77.0M |
| Q1 26 | $131.8M | — | ||
| Q4 25 | $1.9M | $-100.8M | ||
| Q3 25 | $73.6M | $-92.7M | ||
| Q2 25 | $29.8M | $-110.7M | ||
| Q1 25 | $76.2M | $-167.8M | ||
| Q4 24 | $29.9M | $-79.5M | ||
| Q3 24 | $53.7M | $-68.6M | ||
| Q2 24 | $43.8M | $-79.0M |
| Q1 26 | 42.3% | — | ||
| Q4 25 | 0.6% | -48.6% | ||
| Q3 25 | 26.6% | -58.0% | ||
| Q2 25 | 10.6% | -66.5% | ||
| Q1 25 | 27.7% | -120.5% | ||
| Q4 24 | 11.4% | -48.3% | ||
| Q3 24 | 23.0% | -49.2% | ||
| Q2 24 | 19.5% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 0.5% | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.3% | 1.0% | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.8% | 1.2% | ||
| Q2 24 | 0.4% | 1.4% |
| Q1 26 | 9.02× | — | ||
| Q4 25 | 0.23× | — | ||
| Q3 25 | 5.21× | — | ||
| Q2 25 | 1.35× | — | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | 2.74× | — | ||
| Q3 24 | 3.57× | — | ||
| Q2 24 | 2.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVLT
| Term-based license | $114.4M | 37% |
| Software-as-a-service | $93.1M | 30% |
| Customer support | $80.9M | 26% |
| Other | $13.1M | 4% |
| Perpetual license | $10.1M | 3% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
